Flexible Data Trimming Improves Performance of Global Machine Learning Methods in Omics-Based Personalized Oncology
暂无分享,去创建一个
Nicolas Borisov | Victor Tkachev | Anton Buzdin | Maxim Sorokin | Constantin Borisov | Andrew Garazha | Nicolas Borisov | M. Sorokin | A. Garazha | Victor Tkachev | A. Buzdin | C. Borisov
[1] Bhupinder Bhullar,et al. Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human , 2015, Oncotarget.
[2] Nikolay Borisov,et al. Individual Drug Treatment Prediction in Oncology Based on Machine Learning Using Cell Culture Gene Expression Data , 2017, ICCBB.
[3] Gastone Castellani,et al. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) , 2015, Oncotarget.
[4] Anthony Boral,et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.
[5] Christopher M. Bishop,et al. Pattern Recognition and Machine Learning (Information Science and Statistics) , 2006 .
[6] M. Dowsett,et al. Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. S. Cramer. The Origins of Logistic Regression , 2002 .
[8] Nicolas Borisov,et al. New Paradigm of Machine Learning (ML) in Personalized Oncology: Data Trimming for Squeezing More Biomarkers From Clinical Datasets , 2019, Front. Oncol..
[9] Nicolas Borisov,et al. Shambhala: a platform-agnostic data harmonizer for gene expression data , 2019, BMC Bioinformatics.
[10] Nikolay M. Borisov,et al. Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs , 2019, Front. Pharmacol..
[11] G. Molenberghs,et al. Type I and Type II Error Under Random‐Effects Misspecification in Generalized Linear Mixed Models , 2007, Biometrics.
[12] Hae-Young Kim. Statistical notes for clinical researchers: Type I and type II errors in statistical decision , 2015, Restorative dentistry & endodontics.
[13] Yuan Qi,et al. Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial , 2012, BMC Medical Genomics.
[14] J. Jakobsen,et al. Trial Sequential Analysis in systematic reviews with meta-analysis , 2017, BMC Medical Research Methodology.
[15] Amir Samii,et al. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs. , 2018, Seminars in cancer biology.
[16] Federico Girosi,et al. An improved training algorithm for support vector machines , 1997, Neural Networks for Signal Processing VII. Proceedings of the 1997 IEEE Signal Processing Society Workshop.
[17] John P A Ioannidis,et al. Optimal type I and type II error pairs when the available sample size is fixed. , 2013, Journal of clinical epidemiology.
[18] Mary Goldman,et al. The UCSC Cancer Genomics Browser: update 2015 , 2014, Nucleic Acids Res..
[19] M. Sorokin,et al. RNA sequencing for research and diagnostics in clinical oncology. , 2020, Seminars in cancer biology.
[20] T. Reynoldson,et al. Evaluating the Type II error rate in a sediment toxicity classification using the Reference Condition Approach. , 2011, Aquatic toxicology.
[21] S. Stigler,et al. The History of Statistics: The Measurement of Uncertainty before 1900 , 1986 .
[22] Nicolas Borisov,et al. High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology , 2019, Cancer informatics.
[23] Yuan Qi,et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. , 2011, Journal of the National Cancer Institute.
[24] Rieko Arimoto,et al. Development of CYP3A4 Inhibition Models: Comparisons of Machine-Learning Techniques and Molecular Descriptors , 2005, Journal of biomolecular screening.
[25] Nicolas Borisov,et al. A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation , 2015, Oncotarget.
[26] M. Hazinski,et al. Guidelines based on fear of type II (false-negative) errors. Why we dropped the pulse check for lay rescuers. , 2000, Resuscitation.
[27] Yi Li,et al. Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma , 2014, Leukemia.
[28] David C. Atkins,et al. Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia , 2007, Clinical Cancer Research.
[29] M. Hazinski,et al. Guidelines based on fear of type II (false-negative) errors : why we dropped the pulse check for lay rescuers. , 2000, Circulation.
[30] Alex Zhavoronkov,et al. A method of gene expression data transfer from cell lines to cancer patients for machine-learning prediction of drug efficiency , 2018, Cell cycle.
[31] Thomas Lengauer,et al. Classification with correlated features: unreliability of feature ranking and solutions , 2011, Bioinform..
[32] Zhi Wei,et al. A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction , 2018, J. Bioinform. Comput. Biol..
[33] George Potamias,et al. Gene Selection via Discretized Gene-Expression Profiles and Greedy Feature-Elimination , 2004, SETN.
[34] John Shawe-Taylor,et al. Generalization Performance of Support Vector Machines and Other Pattern Classifiers , 1999 .
[35] D B Evans,et al. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole , 2010, The Pharmacogenomics Journal.
[36] Richard A. Moore,et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. , 2015, Cancer cell.
[37] R. Tibshirani. The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.
[38] N. V. Zhukov,et al. Targeted therapy in the treatment of solid tumors: Practice contradicts theory , 2008, Biochemistry (Moscow).
[39] K. Camphausen,et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer , 2010, Breast Cancer Research and Treatment.
[40] Nicolas Borisov,et al. Prediction of Drug Efficiency by Transferring Gene Expression Data from Cell Lines to Cancer Patients , 2017, Braverman Readings in Machine Learning.
[41] Ilya Muchnik,et al. FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier , 2019, Front. Genet..
[42] P. Esker,et al. Statistical Power in Plant Pathology Research. , 2018, Phytopathology.
[43] L. Pusztai,et al. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers , 2014, Breast Cancer Research and Treatment.
[44] Alex Deng,et al. A note on Type S/M errors in hypothesis testing. , 2019, The British journal of mathematical and statistical psychology.
[45] Parantu K. Shah,et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.
[46] Turki Turki,et al. Clinical intelligence: New machine learning techniques for predicting clinical drug response , 2019, Comput. Biol. Medicine.
[47] Gary D Bader,et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer , 2012, Proceedings of the National Academy of Sciences.
[48] Markus Müller,et al. Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? , 2009, Expert review of proteomics.
[49] Leming Shi,et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors , 2010, Breast Cancer Research.
[50] K. Tomczak,et al. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.
[51] F. Santosa,et al. Linear inversion of ban limit reflection seismograms , 1986 .
[52] Abraham Yosipof,et al. Data Mining and Machine Learning Models for Predicting Drug Likeness and Their Disease or Organ Category , 2018, Front. Chem..
[53] Zhi Wei,et al. A link prediction approach to cancer drug sensitivity prediction , 2017, BMC Systems Biology.
[54] Solomon Tesfamariam,et al. Predicting copper concentrations in acid mine drainage: a comparative analysis of five machine learning techniques , 2013, Environmental Monitoring and Assessment.
[55] W. Miller,et al. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole , 2010, Breast Cancer Research.
[56] Houman Owhadi,et al. Optimal uncertainty quantification for legacy data observations of Lipschitz functions , 2012, ArXiv.
[57] L. Esserman,et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.
[58] Zhi Wei,et al. Transfer Learning Approaches to Improve Drug Sensitivity Prediction in Multiple Myeloma Patients , 2017, IEEE Access.
[59] Roman M. Balabin,et al. Support vector machine regression (LS-SVM)--an alternative to artificial neural networks (ANNs) for the analysis of quantum chemistry data? , 2011, Physical chemistry chemical physics : PCCP.
[60] C. Anders,et al. Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma , 2016, Cancer.
[61] Alioune Ngom,et al. A Machine Learning Approach for Identifying Gene Biomarkers Guiding the Treatment of Breast Cancer , 2019, Front. Genet..
[62] S. Stigler,et al. The History of Statistics: The Measurement of Uncertainty before 1900 by Stephen M. Stigler (review) , 1986, Technology and Culture.
[63] Roman M. Balabin,et al. Interpolation and extrapolation problems of multivariate regression in analytical chemistry: benchmarking the robustness on near-infrared (NIR) spectroscopy data. , 2012, The Analyst.
[64] Hongbin Yang,et al. In Silico Prediction of Blood–Brain Barrier Permeability of Compounds by Machine Learning and Resampling Methods , 2018, ChemMedChem.
[65] H. Chitsaz,et al. DeePathology: Deep Multi-Task Learning for Inferring Molecular Pathology from Cancer Transcriptome , 2018, Scientific Reports.
[66] Houman Owhadi,et al. Optimal Uncertainty Quantification , 2010, SIAM Rev..
[67] Shinzaburo Noguchi,et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER‐negative breast cancer , 2012, Cancer science.
[68] L. Pusztai,et al. Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer , 2013, Clinical Cancer Research.
[69] Geert Molenberghs,et al. Type I and Type II Error Under Random‐Effects Misspecification in Generalized Linear Mixed Models , 2007, Biometrics.
[70] Melanie Hilario,et al. Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents , 2004, Proteomics.